Drug combo before and after surgery could boost liver cancer outcomes
NCT ID NCT04930315
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study investigates whether combining two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before and after surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination before surgery, followed by camrelizumab alone after surgery, and are compared to those receiving only camrelizumab after surgery. The goal is to see if this approach reduces the chance of cancer returning or progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab and apatinib mesylate
- What this could lead to
- If successful, this approach could improve survival and reduce recurrence for people with liver cancer who are eligible for surgery.
- What could go wrong
- This is a Phase 2 trial with a small number of participants, so results may not be definitive. The combination therapy may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?
- A machine that keeps donor livers alive outside the body — could it transform transplantation?